Wat is de prijs voor Pell Bio-Med Technology Co., Ltd. (6949)

Het prijs van Pell Bio-Med Technology Co., Ltd. (6949) is $47.38

Wat is de marktkapitalisatie voor Pell Bio-Med Technology Co., Ltd. (6949)

Marktkapitalisatie voorPell Bio-Med Technology Co., Ltd. (6949) is $3.11B

Pell Bio-Med Technology Co., Ltd. (6949) Winst

Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Winst

Winstverschil

Land